Arcutis Biotherapeutics
ARQT
ARQT
133 hedge funds and large institutions have $347M invested in Arcutis Biotherapeutics in 2023 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 50 increasing their positions, 25 reducing their positions, and 40 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
133
Holders Change
-1
Holders Change %
-0.75%
% of All Funds
1.95%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
40
Increased
50
Reduced
25
Closed
40
Calls
$562K
Puts
$557K
Net Calls
+$5K
Net Calls Change
+$3.08M
Top Buyers
| 1 |
Morgan Stanley
New York
|
$39.3M |
| 2 |
SCM
Suvretta Capital Management
New York
|
$27.4M |
| 3 |
Jennison Associates
New York
|
$29.3M |
| 4 |
Franklin Resources
San Mateo,
California
|
$15M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
$20.3M |
Top Sellers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
$3.95M |
| 2 |
O
OrbiMed
New York
|
$0 |
| 3 |
State Street
Boston,
Massachusetts
|
$4.93M |
| 4 |
Marshall Wace
London,
United Kingdom
|
$307K |
| 5 |
Holocene Advisors
New York
|
$0 |
